Pharma, Biotech had outstanding export performance last year

The export performance of 30 listed pharmaceutical and biotechnology companies increased KRW 5.5 trillion→ KRW 6.5 trillion

Samsung Biologics KRW 2.8 trillion→KRW 3.6 trillion 'UP'…15 pharmaceutical companies’ export performance↑

Chong Kun Dang Pharm, a 2.6-fold growth due to technology exports…13 companies with over KRW 100 billion-worth exports

It is reported that 30 of the listed pharmaceutical and biotechnology companies achieved a year-over-year (YoY) growth of 18% in export performance.

 

Samsung Biologics’ exports significantly increased from KRW 2.85 trillion in 2022 to KRW 3.58 trillion last year.

 

SK Biopharmaceuticals, ST Pharm, and Hanmi Pharmaceutical also experienced notable rises in export performance.

 

Chon Kun Dang Pharmaceutical’s large-scale technology export last year impacted its export figures, which represented an increase of 2.6-fold over a year.

 

30 major pharmaceutical companies have experienced an 18% increase in export performance…Samsung Biologics has exceeded KRW 3.5 trillion in export figures According to the Financial Supervisory Service on April 11, thirty major pharmaceutical and biotechnology companies generated the total export figure of KRW 6.52 trillion last year.

 

It was an 18% increase compared to KRW 5.52 in 2022.

 

The data was collected from 30 pharmaceutical and biotechnology companies primarily focused on pharmaceutical businesses listed on the South Korean stock market (KOSPI) and the KOSDAQ stock market.

 

Celltrion and its subsidiaries, which had not publicly disclosed their export performance in business reports, were excluded from the counting.

 

The export performances of 30 major pharmaceutical and biotechnology companies have seen a notable increase recently.

 

The total export figures were KRW 2.65 trillion in 2020, KRW 3.65 trillion in 2021, and KRW 5.52 trillion in 2022.

 

Last year, they exceeded KRW 6.5 trillion, a 2.5-fold increase within the past three years.

 

Samsung Biologics has exceeded KRW 3.5 trillion in export figures.

Samsung Biologics is driving this upward trend.

 

Its export figure surged from KRW 868.2 billion in 2020 to KRW 1.22 trillion in 2021, KRW 2.85 trillion in 2022, and KRW 3.58 trillion last year.

 

Notably, exports to Europe have been surged.

 

Last year, exports to Europe amounted to KRW 2.35 trillion, representing an increase of 32% compared to KRW 1.86 trillion in 2022.

 

Samsung Biologics' exports to Europe exceeded KRW 500 billion in 2020 and soared to KRW 1.8 trillion in just two years.

 

Furthermore, it recorded over KRW 2.3 trillion last year, a 4.5-fold increase over the past three years.

 

Exports to North America expanded from KRW 289.5 billion in 2020 to KRW 448.6 in 2021 and then to KRW 854 in 2022.

 

Last year, the export figure was KRW 971.1 billion, nearing KRW 1 trillion.

 

Exports to countries other than Europe and North America amounted to KRW 19.3 billion in 2021, but it surged to KRW 255.1 billion last year.

 

The upward trend in Samsung Biologics' export performance is expected to continue.

 

At the end of last year, Samsung Biologics' cumulative order amount was US$12.03 billion (approximately KRW 16.3 trillion).

 

Among them, Samsung Biologics delivered US$6.1 billion (approximately KRW 8.3 trillion), with the remaining orders totaling US$5.93 billion (approximately KRW 8.4 trillion).

 

If the client succeeds in product development, the backlog of orders will increase to US$12.36 billion (approximately KRW 16.75 trillion).

 

With the addition of new contracts this year, Samsung Biologics' backlog of orders is expected to further increase.

 

SK Biopharmaceuticals·Hanmi achieved over 30% increase in export figures…With ’large-scale technology exports,’ CKD had a 2.6-fold increase in performance The export performance of 29 companies, excluding Samsung Biologics, amounted to KRW 2.68 trillion in 2022 and then increased over 10% to KRW 2.94 trillion last year.

 

Compared to their KRW 1.78 in 2020, they saw a 1.7-fold increase over the past three years.

 

In particular, SK Biopharmaceuticals, Hanmi Pharmaceutical, and Chong Kun Dang Pharm have shown notable growth in export performance.

 

SK Biopharmaceuticals' export figure increased by 44% from KRW 246.2 billion in 2022 to KRW 354.9 billion last year, driven by expanded prescription of the anti-seizure medication 'Cenobamate' in the North American market.

 

Revenue from Cenobamate and sleep disorders medication 'Solriamfetol' increased by 46%, from KRW 192.9 billion to KRW 282.3 billion.

 

Additionally, export performance from contract manufacturing for global partners increased by 36%, from KRW 53.2 billion to KRW 72.6 billion.

 

Hanmi Pharmaceutical's export figure increased by 37% from KRW 147.7 billion in 2022 to KRW 202.6 billion last year.

 

Exports increased by 70%, from KRW 25.5 billion to KRW 43.3 billion, while exports of raw materials and pharmaceutical ingredients increased by 13%, from KRW 118.6 billion to KRW 133.8 billion.

 

Technology exports, which stood at KRW 3.6 billion in 2022, increased significantly to KRW 25.5 billion last year.

 

Chong Kun Dang Pharm's export figure increased 2.6-fold, from KRW 65.1 billion to KRW 169.4 billion over the past year, due to a large-scale technology export contract signed at the end of last year.

 

In November last year, Chong Kun Dang Pharm signed a technology export contract with Novartis for the histone deacetylase 6 (HDAC6) inhibitor 'CKD-510'.

 

Under this contract, Chong Kun Dang Pharm received an upfront payment of US$80 million (approximately KRW 106.1 billion), and it agreed to receive milestone payments totaling US$1.23 billion (approximately KRW 1.6 trillion) and sales royalties based on future development and approval stages.

 

Trends in the export performance of 30 listed pharmaceutical and biotechnology companies.

 

Samsung Biologics, SK Biopharm, GC Labs, ST Pharm, Yuhan, SK Biosciences, Hanmi Pharmaceutical, Hugel, Chong Kun Dang Pharm, Daewoong Pharmaceutical, Dong-A ST, Medytox, Kolon Life Science, PharmaResearch, DongKook Pharmaceutical, Huons, Kyongbo Pharmaceutical, Il-Yang Pharmaceutical, HK inno.N, JW Pharmaceutical, and others (from the top).

In addition, PharmaResearch and Huons saw an increase in export performance by over 60%.

 

PharmaResearch's export figure increased by 65% from KRW 56.1 billion to KRW 92.8 billion, generated from medical devices such as Rejuran and Conjuran.

 

Huons' export performance increased by 62% from KRW 34.2 billion to KRW 55.5 billion, driven by exports of local anesthetics to the North American market.

 

The export figures of Yuhan, ST Pharm, Huons, Daewoong Pharmaceutical, Medytox, Dongkook Pharmaceutical, Kwangdong Pharmaceutical, and Daehan New Pharm increased by more than 10%.

 

Il-Yang Pharmaceutical and JW Pharmaceutical also saw an increase in export performance compared to the previous year.

 

Among 30 companies, 13 companies, including Samsung Biologics, SK Biopharm, GC Labs, ST Pharm, Yuhan, SK Biosciences, Hanmi Pharmaceutical, Hugel, Chong Kun Dang Pharm, Daewoong Pharmaceutical, Dong-A ST, Medytox, and Kolon Life Science, achieved export figures amounted to KRW 100 billion last year.